This advertisement has not loaded yet, but your Article continues below.
Related Articles
Author of the article:
Article content
The National Institutes of Health has initiated a late-stage study to test plasma-derived COVID-19 therapies including Emergent BioSolutions Inc’s candidate for those at high risk of disease progression, the drug developer said.
Emergent said on Wednesday the study will evaluate the safety and efficacy of polyclonal antibodies derived from plasma of individuals who have recovered from COVID-19.
The trial will include immunocompromised adults and those above 55 years.
Emergent is one of the two companies providing plasma-derived products for the trial, which will enroll approximately 800 patients across the United States and international clinical trial sites.
Emergent’s candidate, COVID-HIG, is in development through funding from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and the Biomedical Advanced Research and Development Authority. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
This advertisement has not loaded yet, but your Article Continues below.
Article content
The Logic
In-depth reporting on the innovation economy from The Logic, brought to you in partnership with the Financial Post.
Financial Post Top Stories
Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
